

Resource Summary Report

Generated by [RRID](#) on Aug 26, 2026

pBabe-Kras Wt

RRID:Addgene_75282

Type: Plasmid

Proper Citation

RRID:Addgene_75282

Plasmid Information

URL: <http://www.addgene.org/75282>

Proper Citation: RRID:Addgene_75282

Insert Name: KRAS

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Vector Backbone Description: Backbone Size:5169; Vector Backbone:pBabe; Vector Types:Mammalian Expression, Retroviral; Bacterial Resistance:Ampicillin

Plasmid Name: pBabe-Kras Wt

Relevant Mutation: None. Wild-Type

Record Creation Time: 20220422T222457+0000

Record Last Update: 20260815T081944+0000

Ratings and Alerts

No rating or validation information has been found for pBabe-Kras Wt.

No alerts have been found for pBabe-Kras Wt.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Mateo-Victoriano B, et al. (2025) Oncogenic KRAS addiction states differentially influence MTH1 expression and 8-oxodGTPase activity in lung adenocarcinoma. *Redox biology*, 82, 103610.

Kramer-Drauberg M, et al. (2025) Oncogenic mutant KRAS inhibition through oxidation at cysteine 118. *Molecular oncology*, 19(2), 311.

Shin DH, et al. (2025) Targeting TGF- β -Smad2/3-JNK1-mediated SIRT1 activity overcomes the chemoresistance of KRAS mutation lung cancer. *Experimental & molecular medicine*, 57(9), 2022.

De Rosa E, et al. (2025) Development of an HPLC-HRMS Method for the Identification and Semi-Quantitation in River Water Samples of the Transformation Products Originated From Heterogeneous Photocatalysis of Antipsychotic Drugs. *Journal of separation science*, 48(10), e70299.

Gong Z, et al. (2024) Brusatol attenuated proliferation and invasion induced by KRAS in differentiated thyroid cancer through inhibiting Nrf2. *Journal of endocrinological investigation*, 47(5), 1271.

Entriago-Cadierno R, et al. (2023) The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer. *Molecular cancer*, 22(1), 86.

Shin DH, et al. (2023) Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer. *Experimental & molecular medicine*, 55(10), 2220.

Gutierrez-Ruiz OL, et al. (2023) Ectopic expression of DOCK8 regulates lysosome-mediated pancreatic tumor cell invasion. *Cell reports*, 42(9), 113042.

Ricciuti B, et al. (2022) Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(8), 1640.

Tripathi P, et al. (2022) Pixantrone confers radiosensitization in KRAS mutated cancer cells by suppression of radiation-induced prosurvival pathways. *Free radical biology & medicine*, 190, 351.

Li R, et al. (2021) Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. *Nature nanotechnology*, 16(7), 830.

Mysore VP, et al. (2021) A structural model of a Ras-Raf signalosome. *Nature structural & molecular biology*, 28(10), 847.

Sad K, et al. (2021) Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation. *Free radical biology &*

medicine, 177, 299.

Zhou ZW, et al. (2020) KRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non-Small Cell Lung Cancer. *Cancer research*, 80(17), 3719.

Inoue S, et al. (2019) Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. *Nature communications*, 10(1), 5785.

Kalvala A, et al. (2019) Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. *Journal of clinical medicine*, 8(10).

Li S, et al. (2018) Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 24(19), 4854.

Ambrogio C, et al. (2018) KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. *Cell*, 172(4), 857.

Zeng M, et al. (2017) Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. *Cell chemical biology*, 24(8), 1005.

Mulcahy Levy JM, et al. (2017) Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. *eLife*, 6.